Enimmune corporation (TPEX:6564)

Market Cap	1.19B
Revenue (ttm)	39.92M
Net Income (ttm)	-157.55M
Shares Out	72.13M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,251
Average Volume	121,135
Open	16.50
Previous Close	16.50
Day's Range	16.15 - 16.50
52-Week Range	16.15 - 49.30
Beta	0.54
RSI	32.70
Earnings Date	May 13, 2025

About Enimmune corporation

Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6564

Financial Performance

In 2024, Enimmune corporation's revenue was 39.92 million, a decrease of -8.23% compared to the previous year's 43.49 million. Losses were -157.55 million, -29.59% less than in 2023.